ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
ARPOD-CV DRY SYP

URSOCALM-300

Product Packing: 10X1X10

Product Composition: Ursodeoxycholic acid 300 mg

Product Price: MRP : 0

URSOCALM-300 Tablets

Ursodeoxycholic Acid 300 mg Tablets

URSOCALM-300 is a prescription formulation containing Ursodeoxycholic Acid 300 mg. Ursodeoxycholic acid (ursodiol) is a hydrophilic bile acid used in selected hepatobiliary conditions according to approved indications and individual clinical assessment.

Ursodeoxycholic acid modifies the composition and flow of bile and can reduce the relative concentration of more hydrophobic bile acids. Treatment selection, dose and duration depend on the specific diagnosis and should follow the approved product label and qualified medical advice.

Composition

Each tablet contains:

·         Ursodeoxycholic Acid - 300 mg

·         Excipients - q.s.

 

Dosage form: Tablet

Pack size: 10 x 1 x 10 tablets

Uses of URSOCALM-300

URSOCALM-300 may be prescribed for selected hepatobiliary conditions where Ursodeoxycholic Acid therapy is approved and clinically appropriate.

·         Management of selected cholestatic liver conditions according to approved prescribing information

·         Dissolution of selected cholesterol gallstones in appropriately assessed patients where indicated

·         Support of bile flow and modification of bile composition in approved clinical settings

·         Other approved uses of Ursodeoxycholic Acid as determined by the treating clinician

Gallbladder, bile-duct or liver symptoms require appropriate diagnosis. URSOCALM-300 should not be used for self-treatment.

How URSOCALM-300 Works

URSOCALM-300 contains Ursodeoxycholic Acid, a hydrophilic bile acid:

Bile composition: Ursodeoxycholic Acid can reduce the relative proportion of more hydrophobic bile acids and modify the bile-acid pool.

Cholesterol handling: It can reduce cholesterol saturation of bile, an action relevant to selected cholesterol gallstones.

Bile flow: Ursodeoxycholic Acid can support bile secretion and bile flow in selected cholestatic conditions.

Clinical response depends on the underlying condition, dose, duration and individual patient factors.

Dose selection and treatment duration must follow the approved product label and prescribing clinician's advice.

 

Dosage and Direction for Use

Use URSOCALM-300 exactly as prescribed. The required dose and duration vary according to the indication, body weight, clinical response and other patient factors.

Swallow the tablet with water and take it at the time and frequency directed by the prescriber. Follow label instructions regarding administration with meals.

Do not increase, reduce or discontinue treatment without consulting the treating healthcare professional.

Long-term therapy may require periodic clinical and laboratory monitoring according to the indication and approved prescribing information.

Possible Side Effects

Possible unwanted effects may include:

·         Diarrhoea or loose stools

·         Abdominal discomfort, nausea or other gastrointestinal symptoms

·         Headache, dizziness or other less common symptoms may occur

·         Rare hypersensitivity or other clinically significant adverse effects may occur

·         Seek medical advice for persistent diarrhoea, severe abdominal pain, worsening jaundice, allergic symptoms or other significant reactions.

Report persistent or troublesome adverse effects to the treating healthcare professional.

Precautions and Contraindications

Before using URSOCALM-300, the prescriber should review the diagnosis, biliary anatomy, liver status and concomitant medicines. Important precautions include:

Do not use in patients with known hypersensitivity to Ursodeoxycholic Acid or formulation ingredients.

·         Certain obstructive biliary conditions, acute inflammation of the gallbladder or biliary tract, or other contraindicated hepatobiliary conditions require specialist assessment and may make treatment unsuitable.

·         For gallstone-related treatment, suitability depends on stone type, size, gallbladder function and other clinical factors.

·         Liver-function monitoring may be required during therapy depending on the indication and clinical situation.

·         Some bile-acid binding agents or aluminium-containing antacids can reduce absorption and may require dose separation according to professional advice.

·         Pregnancy, breastfeeding, children, older adults and patients with significant liver or biliary disease require individualized professional guidance.

·         Keep out of reach of children and store according to the approved pack instructions.

·         Drug Interaction Considerations

·         Ursodeoxycholic Acid absorption may be reduced by bile-acid sequestrants such as cholestyramine or colestipol and by some aluminium-containing antacids. Other clinically relevant interactions depend on the patient's medicines and condition.

·         Patients should provide the prescriber with a complete list of prescription medicines, OTC products and supplements before starting therapy.

Business Growth Opportunity with URSOCALM-300

URSOCALM-300 offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add an Ursodeoxycholic Acid 300 mg prescription tablet to their gastro-hepatology product portfolio.

Hepatobiliary care is an established specialist healthcare segment. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

 

Key Business Advantages

·         Single-ingredient hepatobiliary formulation

·         Ursodeoxycholic Acid 300 mg

·         Established hydrophilic bile-acid molecule

·         Convenient tablet dosage form

·         Suitable addition to gastroenterology and hepatology prescription portfolios

·         Opportunity for ethical promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for URSOCALM-300

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for URSOCALM-300 in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

 

Franchise Support May Include

·         Monopoly-based territory opportunities, subject to availability

·         Promotional materials and visual aids

·         Product information and marketing support

·         Reliable supply coordination

·         Access to a growing pharmaceutical product portfolio

·         Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for URSOCALM-300 and other quality-focused healthcare products.

Third-Party Manufacturing Support for Ursodeoxycholic Acid 300 mg Tablets

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to URSOCALM-300 under their own brand, subject to applicable licensing, prescription-drug, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

·         Customized product and pack requirements, subject to regulatory feasibility

·         Private-label manufacturing opportunities

·         Customized packaging and branding support

·         Product label and pack configuration assistance

·         Manufacturing coordination through suitable licensed facilities

·         Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand a gastro-hepatology prescription product portfolio.

Frequently Asked Questions About URSOCALM-300

1. What is URSOCALM-300?

URSOCALM-300 is a tablet formulation containing Ursodeoxycholic Acid 300 mg.

2. What is URSOCALM-300 used for?

It may be prescribed for selected hepatobiliary conditions, including certain cholestatic conditions or selected cholesterol gallstones, where Ursodeoxycholic Acid is approved and clinically appropriate.

3. How should URSOCALM-300 be taken?

Take URSOCALM-300 exactly as prescribed by a qualified healthcare professional. Dose and duration vary according to the indication and individual patient factors.

4. Can URSOCALM-300 cause diarrhoea?

Yes. Diarrhoea or loose stools can occur. Persistent or significant symptoms should be discussed with the treating healthcare professional.

5. Does Ursodeoxycholic Acid require monitoring?

Depending on the indication and duration, the prescriber may recommend clinical assessment and liver-function or other relevant monitoring.

6. Can URSOCALM-300 be used for every type of gallstone?

No. Ursodeoxycholic Acid is suitable only for selected patients and selected cholesterol gallstones. Stone characteristics, gallbladder function and other clinical factors must be assessed.

7. Is a PCD Pharma Franchise available for URSOCALM-300?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Ursodeoxycholic Acid 300 mg tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

URSOCALM-300 product information in this document is for general professional and business information. Exact approved indications, dosage, contraindications, warnings, interactions, monitoring requirements, duration of use, excipients and regulatory status must be verified against the current approved product label and applicable prescribing information before prescribing, dispensing, use or promotion. This document is not a substitute for professional medical advice.

Contact